YL-365 is a highly potent and selective GPR34 antagonist that exhibits excellent activity in neuropathic pain models for the study of neurologic diseases.

Acute toxicity experiments on C57BL/6J mice showed that no mice died after i.p. (intraperitoneally) (200 mg/kg) treatment with YL-365. In a repeated dose toxicity study, following 14 consecutive days i.p. administration of YL-365 twice per day at the dose of 100 mg/kg, mice did not show noticeable change in body weight or any damage in diverse organs. Considering that GPR34 is also expressed in hematological system, the blood cell counts and other blood parameters were examined, and YL-365 did not show any effects on these blood parameters. All these results indicated low toxicity of YL-365 to mice. [1]